Risk ratios of specific cancer types among VKA-treated patients and control population
| Site or type of cancer (ICD-9-CM code) . | Cancer . | Cancer RRs . | ||||||
|---|---|---|---|---|---|---|---|---|
| Observed . | Predicted . | Avoided . | ||||||
| Control subjects (n = 72 777) . | c/1000 . | Exposed (n = 3231) . | c/1000 . | Exposed . | Exposed . | Crude RR . | Age- and sex-adjusted HR . | |
| Upper gastrointestinal (140-145,146-149,150-151) | 504 | 7 | 26 | 8 | 23 | -3 | 1.16 (0.78-1.71) | 1.07 (0.68-1.49) |
| Lower gastrointestinal (152-154) | 1454 | 20 | 66 | 20 | 65 | -1 | 1.02 (0.80-1.30) | 0.91 (0.71-1.17) |
| Liver, gallbladder (155-156) | 364 | 5 | 15 | 5 | 16 | 1 | 0.93 (0.56-1.54) | 0.85 (0.51-1.43) |
| Pancreatic (157) | 238 | 3 | 12 | 4 | 10 | -2 | 1.14 (0.64-2.01) | 1.03 (0.58-1.84) |
| Respiratory tract (160-162) | 1004 | 14 | 40 | 12 | 45 | 5 | 0.90 (0.66-1.23) | 0.78 (0.57-1.07) |
| Skin cancer including melanoma (172-173) | 1108 | 15 | 60 | 19 | 48 | -12 | 1.22 (0.94-1.58) | 0.99 (0.76-1.29) |
| Breast (174-175) | 1146 | 16 | 38 | 12 | 52 | 14 | 0.64 (0.54-1.02) | 0.88 (0.64-1.22) |
| Uterus and other female reproductive (in 45 237 women; 179-184) | 304 | 7 | 12 | 7 | 12 | 0 | 1.06 (0.60-1.86) | 1.02 (0.57-1.81) |
| Renal and urinary tract (188-189) | 1189 | 16 | 50 | 15 | 52 | 2 | 0.95 (0.72-1.25) | 0.80 (0.60-1.06) |
| Prostate (in 30 771 men; 185) | 993 | 34 | 36 | 22 | 55 | 19 | 0.66 (0.47-0.91)* | 0.69 (0.50-0.97)* |
| Leukemia and other blood (200-208) | 730 | 10 | 38 | 12 | 32 | -6 | 1.17 (0.85-1.62) | 1.06 (0.76-1.47) |
| Other (158-159,163-165,170-171,176, 186-187, 190-195, 199) | 528 | 7 | 18 | 6 | 23 | 5 | 0.77 (0.48-1.22) | 0.69 (0.44-1.12) |
| Metastatic disease (196-198) | 1354 | 19 | 55 | 17 | 61 | 6 | 0.91 (0.70-1.19) | 0.85 (0.65-1.12) |
| Any cancer (140-208) | 9741 | 134 | 421 | 130 | 433 | 12 | 0.97 (0.88-1.06) | 0.88 (0.80-0.98)* |
| Site or type of cancer (ICD-9-CM code) . | Cancer . | Cancer RRs . | ||||||
|---|---|---|---|---|---|---|---|---|
| Observed . | Predicted . | Avoided . | ||||||
| Control subjects (n = 72 777) . | c/1000 . | Exposed (n = 3231) . | c/1000 . | Exposed . | Exposed . | Crude RR . | Age- and sex-adjusted HR . | |
| Upper gastrointestinal (140-145,146-149,150-151) | 504 | 7 | 26 | 8 | 23 | -3 | 1.16 (0.78-1.71) | 1.07 (0.68-1.49) |
| Lower gastrointestinal (152-154) | 1454 | 20 | 66 | 20 | 65 | -1 | 1.02 (0.80-1.30) | 0.91 (0.71-1.17) |
| Liver, gallbladder (155-156) | 364 | 5 | 15 | 5 | 16 | 1 | 0.93 (0.56-1.54) | 0.85 (0.51-1.43) |
| Pancreatic (157) | 238 | 3 | 12 | 4 | 10 | -2 | 1.14 (0.64-2.01) | 1.03 (0.58-1.84) |
| Respiratory tract (160-162) | 1004 | 14 | 40 | 12 | 45 | 5 | 0.90 (0.66-1.23) | 0.78 (0.57-1.07) |
| Skin cancer including melanoma (172-173) | 1108 | 15 | 60 | 19 | 48 | -12 | 1.22 (0.94-1.58) | 0.99 (0.76-1.29) |
| Breast (174-175) | 1146 | 16 | 38 | 12 | 52 | 14 | 0.64 (0.54-1.02) | 0.88 (0.64-1.22) |
| Uterus and other female reproductive (in 45 237 women; 179-184) | 304 | 7 | 12 | 7 | 12 | 0 | 1.06 (0.60-1.86) | 1.02 (0.57-1.81) |
| Renal and urinary tract (188-189) | 1189 | 16 | 50 | 15 | 52 | 2 | 0.95 (0.72-1.25) | 0.80 (0.60-1.06) |
| Prostate (in 30 771 men; 185) | 993 | 34 | 36 | 22 | 55 | 19 | 0.66 (0.47-0.91)* | 0.69 (0.50-0.97)* |
| Leukemia and other blood (200-208) | 730 | 10 | 38 | 12 | 32 | -6 | 1.17 (0.85-1.62) | 1.06 (0.76-1.47) |
| Other (158-159,163-165,170-171,176, 186-187, 190-195, 199) | 528 | 7 | 18 | 6 | 23 | 5 | 0.77 (0.48-1.22) | 0.69 (0.44-1.12) |
| Metastatic disease (196-198) | 1354 | 19 | 55 | 17 | 61 | 6 | 0.91 (0.70-1.19) | 0.85 (0.65-1.12) |
| Any cancer (140-208) | 9741 | 134 | 421 | 130 | 433 | 12 | 0.97 (0.88-1.06) | 0.88 (0.80-0.98)* |
HR indicates hazard ratio; ICD-9-CM, International Classification of Diseases, 9th Edition, Clinical Modification; RR, relative risk; and VKA, vitamin K antagonist.
Statistically significant difference.